By IPP Bureau - January 16, 2023

The hospital will have all the modern facilities like modular OT, state of the art medical equipment, labs, etc. It will have OPD and IPD services

By IPP Bureau - January 16, 2023

A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project

By IPP Bureau - January 16, 2023

APAC to see a reduction in imported surgical robotics

By IPP Bureau - January 14, 2023

Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA

By IPP Bureau - January 14, 2023

By IPP Bureau - January 14, 2023

Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world

By IPP Bureau - January 14, 2023

The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%

By IPP Bureau - January 14, 2023

This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.

By IPP Bureau - January 13, 2023

Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs

By IPP Bureau - January 13, 2023

The implementing agency of PMBJP has invited online applications for opening of new Jan Aushadhi Kendras in 651 districts of different States/UTs

By IPP Bureau - January 13, 2023

The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards

By IPP Bureau - January 13, 2023

The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client

By IPP Bureau - January 13, 2023

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults

By IPP Bureau - January 12, 2023

Swiftmelt 1515-I meets performance requirements and secures skin attachment

By IPP Bureau - January 12, 2023

The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.